Clinigen Group plc Director/PDMR Shareholding (9516N)
05 October 2021 - 1:10AM
UK Regulatory
TIDMCLIN
RNS Number : 9516N
Clinigen Group plc
04 October 2021
4 October 2021
Grant of share options and PDMR notification
Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"),
announces that, on 1 October 2021, the following Directors were
granted share options over a total of 118,110 ordinary shares
of
0.1 pence each ("Ordinary Shares"), granted under the Clinigen
Group Long Term Incentive Plan 2015. The options are nil cost
options intended to vest on 1 October 2024 subject to the
achievement of certain performance criteria.
Director/PDMR Number of Total number Total number Total number
share options of share of ordinary of ordinary
granted options now shares now shares (excluding
held held share options)
as % issued
share capital
Shaun Chilton 118,110 732,074 330,044 0.25%
--------------- ------------- ------------- -------------------
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging managerial
responsibilities/person closely associated
a) Name Shaun Chilton
--------------------------- -------------------------------------
2 Reason for the notification
------------------------------------------------------------------
a) Position/status Group Chief Executive Officer
--------------------------- -------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------- -------------------------------------
3 Details of the issuer, emission allowance market
participant, auction platform, auctioneer or
auction monitor
------------------------------------------------------------------
a) Name Clinigen Group plc
--------------------------- -------------------------------------
b) Legal Entity 213800OBIKGI2JYYS227
Identifier
--------------------------- -------------------------------------
4 Details of the transaction(s): section to be
repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and
(iv) each place where transactions have been
conducted
------------------------------------------------------------------
a) Description Ordinary shares of 0.1 pence each
of the financial GB00B89J2419
instrument,
type of instrument
Identification
code
--------------------------- -------------------------------------
b) Nature of the Grant of Options
transaction
--------------------------- -------------------------------------
c) Currency GBP
--------------------------- -------------------------------------
d) Price(s) and Price(s) Volume(s)
volume(s)
--------------------------- ------------------ -----------------
Nil 118,110
--------------------------------------------------- -----------------
e) Aggregated 118,110
information Nil
- Aggregated
volume
- Price
- Aggregated
total
--------------------------- -------------------------------------
f) Date of the 1 October 2021
transaction
--------------------------- -------------------------------------
g) Place of the London Stock Exchange, AIM
transaction
--------------------------- -------------------------------------
-Ends-
For more information, please contact:
Clinigen Group plc +44 (0) 1283 495010
Shaun Chilton, Chief Executive Officer investors@clinigengroup.com
Rob Fox, VP Investor Relations and Corporate
Development
Numis Securities Limited - Nominated Adviser Tel: +44 (0) 20 7260
& Joint Broker 1000
James Black / Garry Levin / Freddie Barnfield c linigen@Numis.com
RBC Capital Markets - Joint Broker Tel: +44 (0) 20 7653
4000
Marcus Jackson / Elliot Thomas
Consilium Strategic Communications
Mary-Jane Elliott / Matthew Cole / Jessica Tel: +44 (0) 20 3709
Hodgson 5700
c linigen@consilium-comms.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global, specialist
pharmaceutical services and products company focused on providing
ethical access to medicines. Its mission is to deliver the right
medicine to the right patient at the right time. The Group operates
from sites in North America, Europe, Africa and the Asia
Pacific.
Clinigen has more than 1,000 employees across five continents in
14 countries, with supply and distribution hubs and operational
centres of excellence in key long-term growth regions. The Group
works with 34 of the top 50 pharmaceutical companies; interacting
with over 5,000 hospitals across more than 120 countries.
For more information on Clinigen, please visit
http://www.clinigen.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHFLFISIRLSIIL
(END) Dow Jones Newswires
October 04, 2021 10:10 ET (14:10 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2023 to Apr 2024
